Emit Imaging

Join us for a live webinar hosted by Endpoints News on April 27 at 11am ET. Industry experts from Emit Imaging, Invicro & REGENXBIO Inc. introduce cryo-fluorescence tomography (CFT), a novel 3D imaging approach and its applications in gene therapy expression and vector biodistribution
Register Here: https://koi-3QNTQ95M7Q.marketingautomation.services/net/m?md=qXS8p4weUS2nHnvztr4xjQeSYInoQaVA

Preclinical tumor metastasis models are common, butare difficult to visualize and subsequently quantify accurately. MRI lacks sensitivity and specificity at early stage metastasis, while PET, SPECT and optical techniques lack resolution. Cryo-Fluorescence Tomography (CFT) is a new ex-vivo imaging modality combining cryo slicing with serial fluorescence and anatomical white light imaging. This technique provides a whole-body molecular 3D data set which shows the extent of metastasis.

The image below shows that bioluminescence imaging has excellent specificity but lacks sufficient resolution to quantify tumor metastases, especially at depth. Cryo-Fluorescence Tomography can be used as an ex-vivo imaging modality to complement bioluminescence imaging and identify small tumors with a resolution down to 20um.

Learn more: https://lnkd.in/g-65qMEa